Actinium Pharmaceuticals Inc is a biotechnology company that focuses on the development of innovative therapies for cancer treatment
The company's primary emphasis is on harnessing the power of targeted radiotherapy, utilizing its proprietary platform to create treatments that deliver radiation directly to cancer cells while minimizing damage to surrounding healthy tissue. By advancing its pipeline of both therapeutic and diagnostic candidates, Actinium aims to improve patient outcomes in hematologic cancers and solid tumors, contributing to the overall evolution of cancer care. The company's efforts are geared towards addressing unmet medical needs in oncology and enhancing the effectiveness of existing treatment modalities.
FDA rejects Actinium Pharmaceuticals' Phase 3 SIERRA trial for Iomab-B's Biologics License Application due to inadequate support despite achieving a statistically significant primary endpoint. Actinium to conduct a new head-to-head study, focusing on r/r AML treatment without crossover allowances.
